Cambridge Epigenetix Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cambridge Epigenetix's estimated annual revenue is currently $17.5M per year.(i)
  • Cambridge Epigenetix's estimated revenue per employee is $155,000

Employee Data

  • Cambridge Epigenetix has 113 Employees.(i)
  • Cambridge Epigenetix grew their employee count by 23% last year.

Cambridge Epigenetix's People

NameTitleEmail/Phone
1
Director Research & DevelopmentReveal Email/Phone
2
Clinical Operations Consultant/Clinical Operations LeadReveal Email/Phone
3
Lab TechReveal Email/Phone
4
ChairReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$17.5M11323%N/AN/A
Add Company

What Is Cambridge Epigenetix?

Cambridge Epigenetix aims to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of the 5-hydroxymethylcytosine (5hmC) epigenetic modification. We utilise innovative technologies, often based on fundamental chemistry, to detect the epigenetic biomarkers that will be most useful in clinical settings. Spun-out of the University of Cambridge in 2012, the Company was founded by Professor Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq), which enables users to quantify, and discriminate between, functionally-distinct DNA modifications – impossible with traditional bisulfite methods. Cambridge Epigenetix is a privately held company headquartered in Cambridge, UK, supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures and the University of Cambridge. The Company is seeking partnerships across a broad range of applications in life sciences, as well as developing its own pipeline. For more information, visit www.cambridge-epigenetix.com or email info@cambridge-epigenetix.com.

keywords:N/A

N/A

Total Funding

113

Number of Employees

$17.5M

Revenue (est)

23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cambridge Epigenetix News

2021-11-03 - Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform

Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform 03-11-2021 Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising genome sequencing, has announced the signing of an $88 million Series D financing, bringing the ...

2021-11-03 - Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform

Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform 03-11-2021 Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising genome sequencing, has announced the signing of an $88 million Series D financing, bringing the ...

2016-03-17 - Google’s GV leads $21M Series B in bioscience firm Cambridge Epigenetix

VC firm GV (née Google Ventures) has made another investment in Europe — its seventh — leading a $21 million Series B round for epigenetic sequencing tech company and Cambridge University spin-out, Cambridge Epigenetix. The U.K.-based bioscience company makes DNA modification analysis tools for ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M11316%N/A
#2
$17.5M113-18%$233M
#3
$11.3M1134%N/A
#4
$20.5M114-1%N/A
#5
$20.5M11448%N/A